Lilly Broadens Its CNS Reach With Rigel RIPK1 Deal
Joins Sanofi And Denali In Class
Executive Summary
The RIPK1 inhibitor class has yet to reach proof-of-concept, but could bolster Lilly’s dogged pursuit of progress in Alzheimer’s disease.
You may also be interested in...
Deal Watch: ICON, PRA Health Form Massive CRO In $12bn Merger
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.
CEOs Face Grilling On Vaccine Supply In EU
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports